The proportion of cases lost-to-follow up declined from 20%% in 2003 to 1 % in 2012 (X trend, P < 0.001).
Also, it suggests that as the CD4 T-cell count declines, vigilant follow up of the anogenital tract is warranted.
However, retention within the cohorts by years of follow up showed a declining trend and ranged from 22%to25%5% over the five year period of follow up.
After 5 years, 25 patients had died, 22 patients declined follow up after baseline assessment and 16 patients were lost to follow up, thus a total of 197 patients remained under active follow up.
As can be seen in Table 2, these patients exhibited poorer naming scores at follow-up (decline from 6.22 5.43 between the two assessment points).
Even though our 'RCT within-a-cohort' design allows us to also follow up those declining, the elimination of postrandomisation declining obviously decreases the risk of bias.
The proportion of mothers who could be contacted on follow up gradually declined over the duration of the project and at six months 79% of mothers provided information.
Estimates were based on a meta-regression analysis of studies tracing patients lost to follow-up in sub-Saharan Africa that found a negative relationship between the overall rate of LTFU and mortality in patients lost to follow-up: mortality at one year among patients lost to follow-up declined from around 60% to 20% as LTFU increased from 5% to 50% [5].
For children receiving > 9 additional amalgam fillings after initial amalgam placement, urinary mercury concentrations remained elevated 2- to 4-fold compared with those of composite controls throughout much of the 7-year follow-up, declining only gradually during this period.
Participants who either survived to the end of the study or entered managed care had significantly less cognitive decline than those who died, although decedents who died within one year after their last follow-up declined less than those who lived longer before dying.
Among cholecystectomy patients, the risks at 5 or more years of follow-up declined for cancers of liver (SIR = 1.1) and extrahepatic bile duct (SIR = 0.7), but were elevated for cancers of ampulla of Vater (SIR = 2.0, CI = 1.0 3.7) and pancreas (SIR = 1.3, CI = 1.1 1.6).
